Valeant definition

Valeant means Valeant Pharmaceuticals International, a Delaware corporation, and its successors.

Valeant or “Respondent” means Valeant Pharmaceuticals International Inc., its directors, officers, employees, agents, representatives, successors, and assigns; and its joint ventures, subsidiaries, divisions, groups and affiliates in each case controlled by Valeant, and the respective directors, officers, employees, agents, representatives, successors, and assigns of each.

Valeant means Valeant Pharmaceuticals International, a Delaware corporation.

Examples of Valeant in a sentence

• I have reviewed this quarterly report on Form 10-Q of Valeant Pharmaceuticals International, Inc.

• Note that in a series of transactions carried out in March and August 2017, Valeant redeemed all the outstanding 6.75% senior notes due 2018.

• Should the drug make it to market, AstraZeneca and Valeant will share profits.

• Canadian firm Valeant will make an up-front payment to AstraZeneca of US$100 million, as well as additional pre-launch milestones of up to US$170 million and further sales related milestone payments of up to US$175 million following launch.

• Valeant will hold the exclusive rights to develop and commercialise brodalumab globally, except in Japan and certain other Asian countries where rights are held by Kyowa Hakko Kirin under a prior arrangement with Amgen (NASDAQ:AMGN), the US pharmaceuticals developer that originated brodalumab.

More Definitions of Valeant

Valeant means the defendant, Valeant Pharmaceuticals International, Inc. and, as the context may require, includes its subsidiaries and affiliates; and

Valeant means Valeant Pharmaceuticals North America, a Delaware corporation and successor in interest to Valeant Research & Development, or any successor in interest.

Valeant means the corporation formerly known as Valeant Pharmaceuticals International Inc. which, as of July 13, 2018, changed its name to Bausch Health Companies Inc.

Valeant or the “Company” means Valeant Pharmaceuticals International, Inc. (now known as Bausch Health Companies Inc.).

Valeant or the “Company”); (ii) that certain letter agreement, dated as of February 25, 2014 (the “February 25 Letter Agreement”), between Pershing Square and Valeant executed in connection with a potential transaction related to Allergan, Inc. (“Allergan”); (iii) that certain letter agreement, dated as of May 30, 2014 (the “May 30 Letter Agreement”), between Pershing Square and Valeant amending the terms of the February 25 Letter Agreement; (iv) that certain offer to exchange, forming part of the registration statement on Form S-4 filed by Valeant with the Securities and Exchange Commission (“SEC”) on June 18, 2014, and any amendments thereto (the “Offer to Exchange”); and (v) that certain Tender Offer Statement on Schedule TO filed by Valeant and AGMS, Inc., a wholly owned subsidiary of Valeant, and PS Fund 1, LLC, an investment fund managed by Pershing Square (“PS Fund 1”), with SEC on June 18, 2014, and any amendments thereto (the “Schedule TO”). PS Fund 1 is considered a co-bidder in the Offer (as defined below). Capitalized terms used herein but not defined herein shall have the meanings given to such terms in the Offer to Exchange and Schedule TO.

Valeant shall have the meaning set forth in the Preamble.

Valeant means Valeant Pharmaceuticals International, Inc., a corporation organized, existing and doing business under and by virtue of the laws of Canada, with its headquarters address located at 2150 Saint Elzear Blvd. West, Laval, Quebec Canada H7L 4A8, and any wholly owned subsidiary of it, including, (i) Valeant Pharmaceuticals Ireland and (ii) Valeant International Bermuda.